Chung S. Management of bleeding in the cirrhotic patient. J Gastroenterol Hepatol. 2002;17:355.
Bhasin DK, Malhi NJ. Variceal bleeding and portal hypertension: much to learn, much to explore. Endoscopy.
2002;34:119.
Thabut D, Bernard-Chabert B. Management of acute bleeding from portal hypertension. Best Pract Res Clin
Gastroenterol. 2007;21:19.
Marti-Carvajal AJ at al. Vitamin K for upper gastrointestinal bleeding in patients with acute or chronic liver
diseases. Cochrane Database Syst Rev. 2012;9:CD00792.
Goulis J, Burroughs AK. Role of vasoactive drugs in the treatment of bleeding oesophageal varices. Digestion.
1999;60(Suppl 3):25.
Wao T et al. Effect of vasopressin on esophageal varices blood flow in patients with cirrhosis: comparisons with
the effects on portal vein and superior mesenteric artery blood flow. J Hepatol. 1996;25:491.
Law AW, Gales MA. Octreotide or vasopressin for bleeding esophageal varices. Ann Pharmacother.
1997;31:237.
de Franchis R. Longer treatment with vasoactive drugs to prevent early variceal re-bleeding in cirrhosis. Eur J
Gastroenterol Hepatol. 1998;10:1041.
Zhou Y et al. Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute
bleeding in patients with portal hypertensive gastropathy: a controlled study. J Gastroenterol Hepatol.
2002;17:973.
Imperiale TF. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal
variceal hemorrhage. Gastroenterology. 1995;109:1289.
Stump DL, Hardin TC. The use of vasopressin in the treatment of upper gastrointestinal haemorrhage. Drugs.
1990;39:38.
Anderson JR, Johnston GW. Development of cutaneous gangrene during continuous peripheral infusion of
vasopressin. Br Med J. (Clin Res Ed). 1983;287:1657.
Gimson AE et al. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute
variceal hemorrhage. Hepatology. 1986;6:410.
Bruha R et al. Double-blind randomized, comparative multicenter study of the effect of terlipressin in the
treatment of acute esophageal variceal and/or hypertensive gastropathy bleeding. Hepatogastroenterology.
2002; 49:1161.
de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on
methodology of diagnosis and therapy in portal hypertension [published correction appears in J Hepatol.
2005;43:547]. J Hepatol. 2005;43:167.
Cales P et al. Early administration of vapreotide for variceal bleeding inpatients with cirrhosis. French Club for
the Study of Portal Hypertension. N EnglJ Med. 2001;344:23.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
Ioannou GN et al. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment
Pharmacol Ther. 2003;17:53.
Dib N et al. Current management of the complications of portal hypertension: variceal bleeding and ascites.
CMAJ. 2006;174:1433.
Lay CS et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients
with cirrhosis. J Gastroenterol Hepatol. 2006;21:413.
Tatemichi M et al. Differences in hemostasis among sclerosing agents in endoscopic injection sclerotherapy. Dig
Dis Sci. 1996;41:562.
Dagher L, Burroughs A. Variceal bleeding and portal hypertensive gastropathy. Eur J Gastroenterol Hepatol.
2001;13:81.
Goff JS. Endoscopic variceal ligation. In: Basow DS, ed. UpToDate. Waltham, MA, 2011.
Villanueva C et al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic
treatment added to somatostatin in acute variceal bleeding. J Hepatol. 2006;45:560.
Sarin SK et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for
esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol. 1997;26:826.
Helmy A, Hayes PC. Review article: current endoscopic therapeutic options in the management of variceal
bleeding. Aliment Pharmacol Ther. 2001;15:575.
Gow PJ, Chapman RW. Modern management of oesophageal varices. Postgrad Med J. 2001;77:75.
Henderson JM et al. Distalsplenorenalshunt versus transjugular intrahepatic portalsystematic shunt for variceal
bleeding: a randomized trial. Gastroenterology. 2006;130:1643.
Tripathi D et al. The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management
of bleeding gastric varices: clinical and haemodynamic correlations. Gut. 2002;51:270.
Hidajat N et al. Transjugular intrahepatic portosystemic shunt and transjugular embolization of bleeding rectal
varices in portal hypertension. AJR Am J Roentgenol. 2002;178:362.
Jovine E et al. Splenoadrenal shunt. An original portosystemic decompressive technique.
Hepatogastroenterology. 2001;48:107.
Soriano G et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
Gastroenterology. 1992;103:1267.
Fernandez J et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis
and hemorrhage. Gastroenterology. 2006;131:1049.
Chavez-Tapia NC et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal
bleeding – an updated Cochrane review. Aliment Pharmacol Ther. 2011;34:509–518.
Vorobioff J et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a
10-year prospective study. Gastroenterology. 1996;111:701.
Escorsell A et al. Predictive value of the variceal pressure response to continued pharmacological therapy in
patients with cirrhosis and portal hypertension. Hepatology. 2000;31:1061.
Uribe M et al. Portal-systemic encephalopathy and gastrointestinal bleeding after cardioselective beta-blocker
(metoprolol) administration to patients with portal hypertension. Arch Med Res. 1995;26:221.
Talwalkar JA, Kamath PS. An evidence-based medicine approach to beta-blocker therapy in patients with
cirrhosis. Am J Med. 2004;116:759.
PascalJP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with
cirrhosis of the liver and esophageal varices [published correction appears in N Engl J Med. 1988;318:994]. N
EnglJ Med. 1987;317:856.
Sarin SK et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary
prophylaxis of variceal bleeding. Am J Gastroenterol. 2005;100:797.
Abraczinskas DR et al. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime
commitment? Hepatology. 2001;34:1096.
Angelico M et al. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term
survival in cirrhosis. Gastroenterology. 1997;113:1632.
Garcia-Pagan JC et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot
receive beta-blockers. Gastroenterology. 2001;121:908.
Vorobioff J et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients:
long-term hemodynamic and renal effects. Hepatology. 1993;18:477.
Merkel C et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of
variceal bleeding in cirrhosis. Gruppo-Triveneto per L’ipertensione portale (GTIP). Lancet. 1996;348:1677.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
Colombo M et al. Beta-blockade prevents recurrent gastrointestinal bleeding in well compensated patients with
alcoholic cirrhosis: a multicenter randomized controlled trial. Hepatology. 1989;9:433.
de la Pena J et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a
multicenter trial. Hepatology. 2005;41:572.
Puente A et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int.
No comments:
Post a Comment
اكتب تعليق حول الموضوع